Profile of QUANTERIX CORP(NASDAQ:QTRX) stock

QUANTERIX CORP14.28

NASDAQ:QTRX (1/27/2023, 7:00:02 PM)-0.18 (-1.24%)

After market: 14.28 0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Life Sciences Tools & Services

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-08 2022-11-08/amc	Earnings (Next)	02-27 2023-02-27
Ins Owners	8.76%	Inst Owners	82.07%
Market Cap	529.14M	Shares	37.05M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	48.89
IPO	12-07 2017-12-07

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum and other fluids. Its Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. The firm also provides contract research services for customers through its Accelerator Laboratory. The Accelerator Laboratory provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. The firm has completed over 1,700 projects for approximately 400 customers from all over the world using its Simoa platforms.